Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EVOLVD: Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients

NCT03734211 is registered in ClinicalTrials.gov with Lars Gullestad as lead sponsor.

NCT NCT03734211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03734211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EVOLVD: Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients
Lead sponsor
Lars Gullestad
Phase
Phase 3
Overall status
Completed
Start date
June 10, 2019
Completion date
May 20, 2023
Enrollment
130 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac allograft vasculopathy